BACKGROUND: Treating the octogenarian and nonagenarian patients who have acute myeloid leukemia (AML) with intensive chemotherapy is controversial. Several models to predict outcome were proposed, including the use of a comorbidity index. However, it is unclear whether the Charlson comorbidity index (CCI) or the hematopoietic cell transplant comorbidity index (HCTCI) is more sensitive. METHODS: The authors analyzed their experience with 92 patients aged >or=80 years who had AML. Patients' pretreatment characteristics and their treatment outcomes were recorded. RESULTS: All patients were offered intensive treatment; 59 patients (64%) were treated intensively with a variety of regimens, whereas 33 patients (36%) elected to receive supportive care. The CCI and the HCTCI had similar predictive ability for outcome in both groups. A multivariate analyses of prognostic factors identified near-normal albumin (48% of patients; 1-year survival rate, >27%) as a favorable factor for the whole cohort, age <83 years (47% of patients; 1-year survival rate, >25%) and nonmonocytic morphology (75% of patients; 1-year survival rate, >26%) as favorable factors for the intensively treated cohort, and bone marrow blasts <46% (50% of patients; 1-year survival rate, >19%) as a favorable factor for patients who received supportive care. CONCLUSIONS: This retrospective analysis was developed to assist in treatment decisions for octogenarian and nonagenarian patients with AML. The findings will need validation in a prospective study. (c) 2009 American Cancer Society.
BACKGROUND: Treating the octogenarian and nonagenarian patients who have acute myeloid leukemia (AML) with intensive chemotherapy is controversial. Several models to predict outcome were proposed, including the use of a comorbidity index. However, it is unclear whether the Charlson comorbidity index (CCI) or the hematopoietic cell transplant comorbidity index (HCTCI) is more sensitive. METHODS: The authors analyzed their experience with 92 patients aged >or=80 years who had AML. Patients' pretreatment characteristics and their treatment outcomes were recorded. RESULTS: All patients were offered intensive treatment; 59 patients (64%) were treated intensively with a variety of regimens, whereas 33 patients (36%) elected to receive supportive care. The CCI and the HCTCI had similar predictive ability for outcome in both groups. A multivariate analyses of prognostic factors identified near-normal albumin (48% of patients; 1-year survival rate, >27%) as a favorable factor for the whole cohort, age <83 years (47% of patients; 1-year survival rate, >25%) and nonmonocytic morphology (75% of patients; 1-year survival rate, >26%) as favorable factors for the intensively treated cohort, and bone marrow blasts <46% (50% of patients; 1-year survival rate, >19%) as a favorable factor for patients who received supportive care. CONCLUSIONS: This retrospective analysis was developed to assist in treatment decisions for octogenarian and nonagenarian patients with AML. The findings will need validation in a prospective study. (c) 2009 American Cancer Society.
Authors: J Tucker; A E Thomas; W M Gregory; T S Ganesan; S T Malik; J A Amess; J Lim; L Willis; A Z Rohatiner; T A Lister Journal: Hematol Oncol Date: 1990 Jan-Feb Impact factor: 5.271
Authors: B Löwenberg; R Zittoun; H Kerkhofs; U Jehn; J Abels; L Debusscher; C Cauchie; M Peetermans; G Solbu; S Suciu Journal: J Clin Oncol Date: 1989-09 Impact factor: 44.544
Authors: J Yates; O Glidewell; P Wiernik; M R Cooper; D Steinberg; H Dosik; R Levy; C Hoagland; P Henry; A Gottlieb; C Cornell; J Berenberg; J L Hutchison; P Raich; N Nissen; R R Ellison; R Frelick; G W James; G Falkson; R T Silver; F Haurani; M Green; E Henderson; L Leone; J F Holland Journal: Blood Date: 1982-08 Impact factor: 22.113
Authors: M A Sekeres; R M Stone; D Zahrieh; D Neuberg; V Morrison; D J De Angelo; I Galinsky; S J Lee Journal: Leukemia Date: 2004-04 Impact factor: 11.528
Authors: Meir Wetzler; Krzysztof Mrózek; Jessica Kohlschmidt; Hervé Dombret; Hartmut Döhner; Sylvain Pilorge; Utz Krug; Andrew J Carroll; Richard A Larson; Guido Marcucci; Wolfgang Hiddemann; Thomas Büchner; Clara D Bloomfield Journal: Haematologica Date: 2013-10-04 Impact factor: 9.941
Authors: Bernard Tawfik; Timothy S Pardee; Scott Isom; Sarunas Sliesoraitis; Allison Winter; Julia Lawrence; Bayard L Powell; Heidi D Klepin Journal: J Geriatr Oncol Date: 2015-10-30 Impact factor: 3.599